These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 23427886)
1. A vaccine to prevent epidemic meningitis in Africa. Viviani S Lancet Infect Dis; 2013 Mar; 13(3):195-6. PubMed ID: 23427886 [No Abstract] [Full Text] [Related]
2. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241 [TBL] [Abstract][Full Text] [Related]
3. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Frasch CE; Preziosi MP; LaForce FM Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119 [TBL] [Abstract][Full Text] [Related]
4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization. Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915 [TBL] [Abstract][Full Text] [Related]
5. Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks? Roberts L Science; 2010 Dec; 330(6010):1466-7. PubMed ID: 21148362 [No Abstract] [Full Text] [Related]
6. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435 [TBL] [Abstract][Full Text] [Related]
7. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256 [TBL] [Abstract][Full Text] [Related]
8. Meningococcal disease control in countries of the African meningitis belt, 2013. Wkly Epidemiol Rec; 2014 May; 89(20):206-14. PubMed ID: 24864346 [No Abstract] [Full Text] [Related]
10. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Decosas J; Koama JB Lancet Infect Dis; 2002 Dec; 2(12):763-5. PubMed ID: 12467693 [TBL] [Abstract][Full Text] [Related]
11. [Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine]. Nicolas P Med Sante Trop; 2012; 22(3):246-58. PubMed ID: 23186941 [TBL] [Abstract][Full Text] [Related]
12. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Colombini A; Badolo O; Gessner BD; Jaillard P; Seini E; Da Silva A Vaccine; 2011 Jul; 29(33):5474-80. PubMed ID: 21641952 [TBL] [Abstract][Full Text] [Related]
18. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Xie O; Pollard AJ; Mueller JE; Norheim G Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866 [TBL] [Abstract][Full Text] [Related]
19. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt. Carod Artal FJ Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213 [TBL] [Abstract][Full Text] [Related]
20. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]